Regulatory approvals, trial data, and major licensing deals in 2026 are accelerating subcutaneous biologics, cutting patient burden and reshaping biopharma strategy.
|Articles|March 2, 2022
Adagene Announces Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates
Author(s)BioPharm International Editors
Adagene has announced SAFEbody multi-target collaboration with Sanofi for novel masked immuno-oncology antibody candidates.
Advertisement
Adagene, a company focused on antibody-based therapies, announced on March 2, 2022 that it is collaborating with Sanofi to generate masked monoclonal and bispecific antibodies. The companies have formed an exclusive license agreement for development and commercialization by Sanofi.
Adagene’s SAFEbody technology will be used for early research activities to develop masked versions of Sanofi candidate antibodies. All later research, product development, and commercialization will be handled by Sanofi.
SAFEbody technology utilizes precision masking technology to address safety and tolerability challenges associated with many antibody therapeutics. This technology can be applied to monoclonal and bispecific antibodies, as well as a wide variety of other therapeutics modalities.
Sanofi will make an upfront payment of $17.5 million to Adagene, as well as potential milestone payments of up to $2.5 billion.
“We are excited to work with Sanofi and unlock the potential of multiple promising yet challenging immuno-oncology targets by applying our SAFEbody precision masking technology, which is validated by extensive preclinical research as well as clinical data from our ADG126 anti-CTLA-4 program,” said Peter Luo, Ph.D., co-founder, CEO, and chairman of Adagene, in a press release. “We are at the forefront of pushing the boundaries of antibody discovery and engineering by leveraging our AI-powered technology platform. This enables dynamic and precise target engagement by our antibody-based therapeutics, which are tailor made to overcome the fundamental challenges in oncology drug development today.”
Source:
Advertisement
Related to this article
Samsung Biologics signed a $262 million contract manufacturing agreement with an undisclosed European pharmaceutical company, extending production commitments through 2033 and lifting the CDMO's cumulative contract value past $21.9 billion.
Solstice Oncology launched with a $225 million Series A financing to advance porustobart, a second-generation, Fc-enhanced CTLA-4 antibody licensed from Harbour BioMed, into neoadjuvant Phase 2 testing for microsatellite-stable colon cancer.
Amgen and AstraZeneca announced that the Phase 3 DeLLphi-305 trial met its primary endpoint, with Imdelltra (tarlatamab) plus Imfinzi (durvalumab) significantly improving overall survival versus durvalumab alone as first-line maintenance therapy for extensive-stage small cell lung cancer — the first phase 3 study of a bispecific T-cell engager to show a survival benefit in this earlier-line setting.
HHS announced four senior FDA leadership selections, including Karim Mikhail as permanent Director of the Center for Biologics Evaluation and Research and Michael Davis as Director of the Center for Drug Evaluation and Research, capping more than a year of turnover at both centers.
Aptar Pharma's Nanopharm business will lead inhaled formulation development and device assessment for ACT-101, Aceso Therapeutics' antisense oligonucleotide candidate designed to correct CFTR protein function in cystic fibrosis patients carrying the F508del mutation.
mAbxience and Sandoz are targeting a $5.7 billion market with a proposed emicizumab biosimilar for hemophilia A.
Fayuvi scored 23.5 points higher than untreated peers on cognitive testing, backing the first-ever approval for a Sanfilippo syndrome A gene therapy.
Advertisement
Advertisement